Business Wire

MAROPOST

21.5.2024 19:16:30 CEST | Business Wire | Press release

Share
Maropost bolsters product leadership team to accelerate innovation and growth

Maropost, the commerce software suite built for fast-growing commerce brands, announces two significant appointments to its senior leadership team: Tim Schulz joins as VP of Product, Commerce Cloud, and Alessandra "Alex" Jacques steps in as VP of Product, Marketing Cloud.

"I founded Maropost to disrupt a crowded market, and with Tim and Alex on board, we are aggressively pursuing that vision," said Maropost Chairman and CEO Ross Andrew Paquette. "We're building a single platform that puts fast-growing retailers in control of their customer journeys, from hyper-personalized marketing to in-store and online purchases through exceptional service.

"Brands will use Maropost to create and manage product catalogs, centrally design and deploy promotions across all their channels, build engaging storefronts, and deliver personalized shopping experiences from one data set, in one nerve center."

Paquette is confident Maropost will achieve this mission. "We're not just another player in the market; we're here to redefine it. Watch closely: We're about to show what's possible when ingenuity meets determination."

About the New Appointees

Alex Jacques brings deep product management expertise from her roles at Terminus and Cheetah Digital. A certified CSM and CSPO, she excels at leading highly functional scrum teams, managing multiple platforms, and driving customer experience strategies. Her marketing technology prowess will shape the future of Marketing Cloud.

Tim Schulz is a seasoned product and technology leader with a track record of delivering outstanding results. As Head of Product at Magento and VTEX, he built products that enabled mid-market and enterprise retailers to scale their businesses globally and respond to shifts in the industry. At BigCommerce, he led Product & Engineering and grew revenue to over $100 million ARR in 24 months while launching strategic partnerships with top tech companies, including Facebook, Twitter, Google, and Alibaba.

Tim was also a top 5% performer at Google, where he led global platform partnerships for Google Shopping and drove 40 full-cycle enterprise deals across product lines. At Maropost, Tim will direct the development of future commerce products.

"We're thrilled to welcome Alex and Tim to the Maropost team," said Sean Brady, COO and President of Maropost. "Their extensive product expertise, proven leadership, and passion for delivering exceptional customer experiences will help us realize our vision of a unified platform that helps them grow, scale, and drive real value from their marketing, commerce, and service efforts."

About Maropost

Only Maropost unites the commerce tools and insights growing brands need to engage customers and scale their business. Built on unified customer data and an enterprise-grade infrastructure, Maropost offers a complete, connected suite of marketing, merchandising and search, customer service, ecommerce, and retail solutions.

Since its founding in 2011, Maropost has made multiple appearances on Deloitte's Technology Fast 500 list and G2's leaderboard. A global company, Maropost proudly serves 5,000+ leading commerce brands across North America, Australia, and Europe, including Victoria Beckham, Sandro Paris, Untuckit, Scott Sports, James Perse, and Fujifilm.

Learn more at www.maropost.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240521528910/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye